EGFR and lung carcinoma: We report a retrospective cohort study of advanced stage non-small lung cancer patients who received subsequent treatment of docetaxel/nintedanib after platinum-resistant advanced stage lung cancer to explore treatment efficacy in terms of EGFR/ALK alteration status and efficacy of treatment following immunotherapy.